Taking advantage of a broken patent system, Big Pharma is making minor tweaks to medications just to keep affordable generics off the market, a new report suggests. They’ve made billions of dollars in ...

Established drugs were repurposed, “me-too” drugs were approved, and even the few new biological approaches lacked clinical ...

Novo shares have surged more than 20% amid oral Wegovy’s fast start. Elsewhere, Terns opened up room for a potential ...

A new generation of malaria drugs failed clinical trials, in part because they were hard to swallow. UCSF chemists remodeled their structures to make them more soluble, while maintaining their ...